share_log

CRISPR Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Kulkarni Samarth

SEC announcement ·  Mar 19 05:46
Summary by Futu AI
On March 15, 2024, Samarth Kulkarni, CEO of CRISPR Therapeutics, completed a stock transaction involving the company's common shares. Kulkarni acquired 20,000 shares through the exercise of derivative securities at a price of $19.12 per share. On the same day, he sold a total of 20,000 shares in two separate open market transactions. The first sale consisted of 10,613 shares at a price of $71.9693 each, while the second involved 9,387 shares sold at $73.0604 per share. Following these transactions, Kulkarni's direct holdings in CRISPR Therapeutics amounted to 208,122 shares. The total market value of the disposed shares was approximately $1,449,628. Additionally, Kulkarni holds an indirect interest in 200,000 shares through The Kulkarni 2023 GRAT, an indirect beneficial ownership structure.
On March 15, 2024, Samarth Kulkarni, CEO of CRISPR Therapeutics, completed a stock transaction involving the company's common shares. Kulkarni acquired 20,000 shares through the exercise of derivative securities at a price of $19.12 per share. On the same day, he sold a total of 20,000 shares in two separate open market transactions. The first sale consisted of 10,613 shares at a price of $71.9693 each, while the second involved 9,387 shares sold at $73.0604 per share. Following these transactions, Kulkarni's direct holdings in CRISPR Therapeutics amounted to 208,122 shares. The total market value of the disposed shares was approximately $1,449,628. Additionally, Kulkarni holds an indirect interest in 200,000 shares through The Kulkarni 2023 GRAT, an indirect beneficial ownership structure.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.